1-20 of 65
Simon Rule
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indirect comparison of bendamustine-rituximab and R-CHOP with rituximab maintenance in first-line treatment of elderly Mantle Cell Lymphoma: Data from the enrich trial

Free
Lexy Sorrell, Toby Eyre, Mats Jerkeman, Simon Rule, Dave Wright, Cathy Burton, Mark Bishton, Andrew Davies, Christopher McNamara, Kristina Sonnevi, Jon Riise, Christian Poulsen, Ingemar Lagerlöf, Ingrid Glimelius, Karin Wader, David Lewis
Journal: Blood
Blood (2025) 146 (Supplement 1): 1822.
https://doi.org/10.1182/blood-2025-1822
Published: 2025
Journal Articles

Conventional quality-of-life data analyses underestimate gains in Mantle Cell Lymphoma clinical trials: A re-examination of enrich study data

Free
Jeremy Hobart, David Andrich, Mats Jerkeman, Toby Eyre, Mark Bishton, Ingrid Glimelius, Annika Pasanen, Andrew Davies, Nick Morley, Christopher McNamara, Cathy Burton, Nicola Crosbie, Christian Poulsen, Karin Wader, Ingemar Lagerlöf, Jacob Christensen, Jon Riise, Kristina Sonnevi, Simon Rule, David Lewis
Journal: Blood
Blood (2025) 146 (Supplement 1): 1804.
https://doi.org/10.1182/blood-2025-1804
Published: 2025
Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Free
Eliza Hawkes, Joanna Romejko-Jarosinska, Wojciech Jurczak, Sunil Iyengar, Abel Costa, Nimish Shah, Monique Menzies Wojtowicz, Allison Winter, Adam Witkowski, Neil Chua, Ana Jiménez Ubieto, John Kuruvilla, Diego Villa, Chan Cheah, Andre Goy, Elise Chong, Andrew Wood, Rachel Fletcher, Stefanie Meyer, Rebecca Silva, Simon Rule, Michael Wang
Journal: Blood
Blood (2025) 146 (Supplement 1): 884.
https://doi.org/10.1182/blood-2025-884
Published: 2025
Journal Articles

Analysis of the role of baseline PET/CT in a prospective study of unselected patients: The UK MCL biobank

Free
Georgina Naylor, Sarah Mant, Asha Omar, Lexy Sorrell, Nicola Crosbie, Peninsula Clinical Trials Unit, Kristian Bowles, Safia Dawi, Christopher McNamara, Melanie Oates, Mark Bishton, Toby Eyre, Andrew Pettitt, Simon Rule, David Lewis
Journal: Blood
Blood (2025) 146 (Supplement 1): 5376.
https://doi.org/10.1182/blood-2025-5376
Published: 2025
Journal Articles

A Prospective Analysis of Outcomes Following Successive Lines of Treatment in Mantle Cell Lymphoma in an Unselected Previously Untreated Population: The UK MCL Biobank

Free
Sarah Mant, Georgina Naylor, Nicola Crosbie, Sree Aroori, Mark J Bishton, Kristian Bowles, Safia Dawi, Toby A. Eyre, Wendy Ingram, Abigail Martin, Christopher McNamara, Melanie Oates, Andrew Pettitt, Claire Scully, Brian Wainman, Mark Warner, Simon Rule, David John Lewis
Journal: Blood
Blood (2024) 144 (Supplement 1): 1641.
https://doi.org/10.1182/blood-2024-209701
Published: 2024
Journal Articles

High-Risk Subgroups and MRD: An Updated Analysis of the Phase 3 ECHO Trial of Acalabrutinib with Bendamustine/Rituximab in Previously Untreated Mantle Cell Lymphoma

Free
Martin Dreyling, Jiri Mayer, David Belada, Yuqin Song, Wojciech Jurczak, Jonas Paludo, Michael P. Chu, Iryna Kryachok, Laura Maria Fogliatto, Chan Y. Cheah, Marta Morawska, Juan-Manuel Sancho, Yufu Li, Caterina Patti, Cecily Forsyth, Jingyang Zhang, Robin Lesley, Safaa Ramadan, Simon Rule, Michael Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 1626.
https://doi.org/10.1182/blood-2024-200290
Published: 2024
Journal Articles

Validation and Implementation of Flow Cytometry Based Minimal Residual Disease (MRD) Assay for Chronic Lymphocytic Leukemia (CLL) Clinical Studies

Free
Christele Gonneau, Marc Brugarolas, Lotje Van Haecht, Marc Lenjou, Caitlyn Fritsche, Yevgeniy Linnik, Lucas Rifkin, Ting Yu, Simon Rule, Veerendra Munugalavadla, Yoav Peretz
Journal: Blood
Blood (2024) 144 (Supplement 1): 6761.
https://doi.org/10.1182/blood-2024-206125
Published: 2024
Journal Articles

Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich

Free
David John Lewis, Mats Jerkeman, Lexy Sorrell, David Wright, Ingrid Glimelius, Annika Pasanen, Jacob Haaber Christensen, Karin Fahl Wader, Andrew J. Davies, Nick Morley, Christopher McNamara, Christian Bjørn Poulsen, Jon Riise, Kristina Sonnevi, Ingemar Lagerlöf, Cathy Burton, Surita Dalal, Andrew Rawstron, Ruth M de Tute, Victoria Allgar, Sree Aroori, Mark Warner, Brian Wainman, Claire Scully, Jeanette Sanders, Carsten Utoft Niemann, Helle Toldbod, Nicola Crosbie, Mark J Bishton, Toby A. Eyre, Simon Rule
Journal: Blood
Blood (2024) 144 (Supplement 1): 235.
https://doi.org/10.1182/blood-2024-199710
Published: 2024
Journal Articles

Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib

Free
Clinical Trials & Observations
Jennifer A. Woyach, Daniel Jones, Wojciech Jurczak, Tadeusz Robak, Árpád Illés, Arnon P. Kater, Paolo Ghia, John C. Byrd, John F. Seymour, Susan Long, Nehad Mohamed, Samon Benrashid, Tzung-Huei Lai, Gary De Jesus, Richard Lai, Gerjan de Bruin, Simon Rule, Veerendra Munugalavadla
Journal: Blood
Blood (2024) 144 (10): 1061–1068.
https://doi.org/10.1182/blood.2023023659
Published: 2024
Includes: Supplemental data
Journal Articles

Extended Follow-up and Resistance Mutations in CLL Patients Treated with Acalabrutinib

Free
Clare Sun, Raghuveer Mali, Rachel Kositsky, Xin Tian, Hannah Tomczak, Barrett Nuttall, Rafael White, Simon Rule, Veerendra Munugalavadla, Adrian Wiestner
Journal: Blood
Blood (2023) 142 (Supplement 1): 1891.
https://doi.org/10.1182/blood-2023-178819
Published: 2023
Journal Articles

Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma

Free
Eliza A Hawkes, Rachel Fletcher, Andrew Wood, Stefanie Meyer, Simon Rule, Jingyang Zhang, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 3054.
https://doi.org/10.1182/blood-2023-174718
Published: 2023
Journal Articles

Analysis of Ventricular Arrhythmias and Sudden Death with Acalabrutinib from 5 Prospective Clinical Trials

Free
Jeff P. Sharman, Paolo Ghia, Paulo Andre P. Palhares De Miranda, Naghmana Bajwa, Simon Rule, Bob Shaw, John F. Seymour
Journal: Blood
Blood (2023) 142 (Supplement 1): 4643.
https://doi.org/10.1182/blood-2023-174913
Published: 2023
Journal Articles

A Multi-Modal Analysis of Acquired Resistance to Acalabrutinib and Pirtobrutinib Provides Potential Strategies to Augment Treatment Outcome with BTKi Drugs

Free
Xiaoyun Wu, Shariful Islam, Derek B Oien, Collin Tokheim, Alex Beacom, Neeraj Aryal, Michelle Hsueh, Muskan Floren, Douglas Ross-Thriepland, Daniel Barrell, Ultan McDermott, Veerendra Munugalavadla, Daniel Auclair, Simon Rule, Arthur Shaffer, Jude Fitzgibbon, Lisa Drew
Journal: Blood
Blood (2023) 142 (Supplement 1): 1452.
https://doi.org/10.1182/blood-2023-189924
Published: 2023
Journal Articles

Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Free
Priyanka Gaitonde, Ling Cai, Paulo de Miranda, Jack Roos, Simon Rule, Michael L. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 3646–3647.
https://doi.org/10.1182/blood-2022-169661
Published: 2022
Journal Articles

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Free
Clinical Trials & Observations
Steven Le Gouill, Franck Morschhauser, David Chiron, Krimo Bouabdallah, Guillaume Cartron, Olivier Casasnovas, Caroline Bodet-Milin, Sylviane Ragot, Céline Bossard, Nathalie Nadal, Charles Herbaux, Benoit Tessoulin, Emmanuelle Tchernonog, Cédric Rossi, Rory McCulloch, Thomas Gastinne, Mary B. Callanan, Simon Rule
Journal: Blood
Blood (2021) 137 (7): 877–887.
https://doi.org/10.1182/blood.2020008727
Published: 2021
Includes: Supplemental data
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study

Free
Michael Wang, MD, Simon Rule, MD PhD, Pier Luigi Zinzani, MD, Andre H. Goy, MD, Rene-Olivier Casasnovas, MD, Stephen D. Smith, MD, Gandhi Laurent Damaj, MD PhD, Jeanette K. Doorduijn, MD PhD, Thierry Lamy, Franck Morschhauser, MD PhD, Carlos Panizo, MD PhD, Bijal Shah, MD, Andrew Davies, MD PhD, Richard Eek, FRACP., Jehan Dupuis, MD, Eric Jacobsen, MD, Arnon P. Kater, MDPhD, Steven Le Gouill, MD PhD, Lucie Oberic, MD, Tadeusz Robak, MDPhD, Preetesh Jain, MBBS,MDDM,PhD, Graham Brock, PhD, Priti Patel, MD, Lin Tao, Monika Dlugosz-Danecka, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-134824
Published: 2020
Journal Articles

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

Free
Pier Luigi Zinzani, MD, Vincent Delwail, Shankara Paneesha, MD, Simon Rule, MD PhD, Alejandro Martin Garcia-Sancho, MD PhD, Ana Marin-Niebla, MD PhD, Gilles Salles, MD PhD, Juan-Manuel Sancho, MD PhD, Vibeke Vergote, MD, Vittorio Ruggero Zilioli, MD, Fred Zheng, MD, Douglas J DeMarini, PhD, Wei Jiang, PhD, Amitkumar Mehta, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–44.
https://doi.org/10.1182/blood-2020-134609
Published: 2020
Journal Articles

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Free
Michael Wang, MD, Jacqueline C. Barrientos, MD, Richard R. Furman, MD, Matthew Mei, MD, Paul M. Barr, MD, Michael Y. Choi, MD, Sven de Vos, MD PhD, Avyakta Kallam, MD, Krish Patel, MD, Simon Rule, MD PhD, Kate Flanders, BS, Katti A. Jessen, PhD, Peter C. Riebling, Patricia Graham, BHSA, Lydia King, PhD, Elizabeth M. Schmidt, BSN, Brian J. Lannutti, PhD, David M. Johnson, BS, Langdon L. Miller, MD, Stephen E. Spurgeon, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-136373
Published: 2020
Journal Articles

Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial

Free
Carla Casulo, Armando Santoro, Kiyoshi Ando, Steven Le Gouill, Jia Ruan, MD PhD, John Radford, Luca Arcaini, Antonello Pinto, Reda Bouabdallah, Koji Izutsu, MD PhD, Simon Rule, Javier Munoz, MD, Marie-Laure Casadebaig, Brian Fox, Nils Rettby, Justine Dell'Aringa, Richard Delarue, Kathryn Newhall, Myron Czuczman, Guillaume Cartron
Journal: Blood
Blood (2019) 134 (Supplement_1): 5320.
https://doi.org/10.1182/blood-2019-124102
Published: 2019
Journal Articles

R-BAC Maintains High Response Rate in Mantle Cell Lymphoma Following Relapse on BTK Inhibitor Therapy

Free
Rory McCulloch, FRCPath, MRCP, MBBS, Carlo Visco, Rebecca Frewin, Neil Phillips, Toby A. Eyre, David Tucker, MD, Francesca M. Quaglia, Annabel McMillan, Jonathan Lambert, Nicola Crosbie, Simon Rule
Journal: Blood
Blood (2019) 134 (Supplement_1): 3989.
https://doi.org/10.1182/blood-2019-129829
Published: 2019